Business
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"Cadrenal Therapeutics Inc.","displaySize":"","headline":null,"caption":"Cadrenal Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/39d76876f0bb492d3ae96512360c5747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O2jr.ga20FAqxm0lkGKePw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/39d76876f0bb492d3ae96512360c5747","width":300,"height":86}},"lazy":false},{"type":"text","content":"PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.","length":433,"tagName":"p"},{"type":"text","content":"Company Webcast","length":15,"tagName":"p"},{"type":"text","content":"The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at https://app.webinar.net/QG1g6kJWEM0. The webcast will also be available for replay following the event.","length":312,"tagName":"p"},{"type":"text","content":"1x1 Meetings","length":12,"tagName":"p"},{"type":"text","content":"Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register for the event at https://lythampartners.com/fall2025invreg/.","length":253,"tagName":"p"},{"type":"text","content":"About Cadrenal Therapeutics, Inc.Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy. Cadrenal’s lead investigational product is tecarfarin, a novel oral Vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoag...